Breakthroughs in Molecular Diagnostics and Cancer Research

Scientists at the Human Genome Project are discovering genetic markers for various diseases, including cancer, at an unprecedented rate. The identification of these disease genes is paving the way for the development of DNA-based diagnostic and prognostic assessments. This momentum is expected to revolutionize the pharmaceutical industry, enabling the creation of targeted therapies and accelerating the drug development process. In cancer research, the discovery of cancer-causing genes is shedding light on novel treatment approaches, such as immunological therapies and genetic-based interventions.

Key Takeaways:

• The Human Genome Project is rapidly identifying genetic markers for diagnosing cancer and genetically inherited disorders.
• These discoveries will enable the development of DNA-based diagnostic and prognostic assessments, revolutionizing the pharmaceutical industry.
• Molecular diagnostics will facilitate the creation of targeted therapies and accelerate the drug development process.
• The identification of cancer-causing genes is driving the development of novel treatment approaches, including immunological therapies and genetic-based interventions.
• Decision Resources is publishing four DR Reports that explore new strategies in cancer diagnosis, drug development, and treatment, including commercial applications of molecular diagnostics and gene therapy technologies.
• The reports examine the potential of emerging biological technologies, such as cell cycle control and apoptosis, to redirect the course of cancer therapy.

Statistics:

• The Human Genome Project is identifying genetic markers at an unprecedented rate.
• Over 40 companies are working to overcome technical barriers to developing genetic tests.
• Decision Resources' reports aim to analyze the commercial prospects for gene therapy technologies, forecasting their potential for commercial success.
• Each report is available for $2750.00 (Molecular Diagnostics, $1800.00), with volume discounts available.
• Decision Resources is an independent, employee-owned health care research and consulting firm founded as a subsidiary of Arthur D. Little, Inc.

Sources:

• PRNewswire, WALTHAM, Mass., May 12 /PRNewswire/ --
• Decision Resources publications: New Strategies in Cancer Therapeutics, New Strategies in In Vitro Cancer Diagnostics, Commercial Applications of Molecular Diagnostics, and The Commercial Prospects for Gene Therapy Technology.
• Decision Resources, Inc. 1100 Winter Street Waltham, MA 02154.